ATNM - actiniumpharma.com Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Actinium Pharma (ATNM) - corporate logo

Actinium Pharmaceuticals (ATNM) leverages a US-based R&D infrastructure to develop targeted radiopharmaceuticals for the treatment of hematologic malignancies. High business margins are sustained by patent rights for bone marrow transplant preparation agents. The implementation of software robots and automated screening accelerates the release of new drugs, and the current market quotes visualized below show an EV/EBITDA value of 1.54.

ATNM Actinium Pharmaceuticals Inc: Company Value to EBITDA in the range 11/23/2025 - 11/16/2026

Actinium Pharmaceuticals, Inc. - analytical breakdowns and key metrics (ATNM)

- current price and projected stock value:
Fundamental company analysis:actiniumpharma.com ATNM
Product sample of actiniumpharma.com

This ratio compares the total enterprise value, including net debt, to operating profit to determine the efficiency of debt coverage. By analyzing the EV/EBITDA ratio from a historical perspective, an investor can assess the overpayment for the assets of Actinium Pharmaceuticals (ATNM), whose development costs for "smart" radiopharmaceuticals for blood cancer therapy require strict liquidity control to minimize default risks.